EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.

Shougeng Liu, Yiting Jiang, Yudong Fu, Simeng Wang, Rao Fu, Minmin Gao, Yingxi Zhao, Sihong Chen, Yuan Yang, Weiming Yang, Lina Jia, Mingze Qin und 3 weitere

Journal for ImmunoTherapy of Cancer · 2026-02 · 14 (2) · e012886

DOI: 10.1136/jitc-2025-012886 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 04.02.2026. Verfasst von Shougeng Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, B7-H1 Antigen, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Basic Scientific Research Project of Department of Education of Liaoning Province, International Industrial Technology Research and Development Project of Liaoning Provincial Department of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acquired resistance to KRAS G12C inhibitor sotorasib remains a critical challenge in non-small cell lung cancer treatment. A deeper, rational understanding of resistance mechanisms can enable the development of therapeutic strategies to overcome resistance.

Methods

We established a syngeneic resistant model after prolonged AMG-510 treatment in C57BL/6 mice. In addition, the in vitro co-culture model and multiple methods including flow cytometry and western blot were used to assess the changes of immune microenvironment during resistance. Finally, a serial combinatorial therapy strategy was applied in the resistant mouse model to evaluate its ability to reverse resistance.

Results

Upregulation of PD-L1 in KRAS G12C tumors drives an immunosuppressive tumor microenvironment and promotes acquired resistance characterized by reduced infiltration of cytotoxic CD8 + T cells and a marked expansion of myeloid-derived suppressor cells through JAK2/STAT3/IL-6 Pathway. These mechanisms promote tumor immune evasion and protection from cell apoptosis, thereby establishing a microenvironment that sustains acquired resistance to sotorasib. Critically, sequential administration of a PD-L1 inhibitor (PD-L1i) effectively reprogrammed the immunosuppressive microenvironment, restoring antitumor immunity and re-sensitizing resistant tumors to sotorasib treatment.

Conclusions

These results identify the PD-L1-driven immunosuppressive microenvironment as a key mediator of sotorasib resistance and propose PD-L1i as a synergistic strategy to overcome resistance, which warrants clinical exploration of sequential or combinatorial regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentB7-H1 AntigenProto-Oncogene Proteins p21(ras)Drug Resistance, NeoplasmLung NeoplasmsAnimalsMiceHumansMice, Inbred C57BLImmune Checkpoint InhibitorsCell Line, Tumor

Stichwörter der Autor:innen

Immune Checkpoint InhibitorLung CancerT-LymphocytesToleranceTumor microenvironment - TME

Substanzen

B7-H1 AntigenProto-Oncogene Proteins p21(ras)Cd274 protein, mouseImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
  • Benxi Institute of Pharmaceutical Research, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
  • Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
  • Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China lhwang@syphu.edu.cn elanorzhang@163.com cuiwei@syphu.edu.cn.
  • Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning, China lhwang@syphu.edu.cn elanorzhang@163.com cuiwei@syphu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Basic Scientific Research Project of Department of Education of Liaoning Province
  • International Industrial Technology Research and Development Project of Liaoning Provincial Department of Science and Technology

Zitieren

APA

Liu, S., Jiang, Y., Fu, Y., Wang, S., Fu, R., Gao, M., Zhao, Y., Chen, S., Yang, Y., Yang, W., Jia, L., Qin, M., Zhang, X., Cui, W., & Wang, L. (2026). Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression. Journal for ImmunoTherapy of Cancer, 14(2), e012886. https://doi.org/10.1136/jitc-2025-012886

Vancouver

Liu S, Jiang Y, Fu Y, Wang S, Fu R, Gao M, et al. Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression. Journal for ImmunoTherapy of Cancer. 2026;14(2):e012886. doi:10.1136/jitc-2025-012886

BibTeX
@article{Liu2026,
  author = {Liu, Shougeng and Jiang, Yiting and Fu, Yudong and Wang, Simeng and Fu, Rao and Gao, Minmin and Zhao, Yingxi and Chen, Sihong and Yang, Yuan and Yang, Weiming and Jia, Lina and Qin, Mingze and Zhang, Xiaohui and Cui, Wei and Wang, Lihui},
  title = {Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {e012886},
  doi = {10.1136/jitc-2025-012886}
}
Kostenlos starten →